

Applicants: Marc Feldmann and Ravinder N. Maini
U.S. Serial No.: Not Yet Known
Filed: Herewith
Page 2

International Application No. PCT/GB93/02070, filed October 6, 1992, which is a continuation-in-part of U.S. Serial No. 07/958,248, filed October 8, 1992, now abandoned, the teachings of all of which are incorporated herein by reference.

In the Claims

Please cancel claims 1-31 without prejudice to applicants' right to pursue the subject matter of these claims in a continuing application.

Please add new claims 32-69 as follows:

32. (New) A method for treating or preventing a tumor necrosis factor-mediated disease in an individual in need thereof comprising co-administering methotrexate and a TNF α antagonist to said individual, in therapeutically effective amounts.
33. (New) The method of Claim 32, wherein said TNF α antagonist and methotrexate are administered simultaneously.
34. (New) The method of Claim 32, wherein said TNF α antagonist and methotrexate are administered sequentially.
35. (New) The method of Claim 32, wherein the tumor necrosis factor-mediated disease is selected from the group consisting of autoimmune disease, acute or chronic immune disease, inflammatory disease and neurodegenerative disease.

Applicants: Marc Feldmann and Ravinder N. Maini
U.S. Serial No.: Not Yet Known
Filed: Herewith
Page 5

52. (New) The method of Claim 51, wherein said soluble TNF α receptor is selected from the group consisting of p55 TNF α receptor and p75 TNF α receptor.
53. (New) The method of Claim 51, wherein said soluble TNF α receptor is a TNF α receptor multimeric molecule.
54. (New) The method of Claim 51, wherein said soluble TNF α receptor is a TNF α receptor immunoreceptor fusion molecule
55. (New) A method for treating or preventing arthritis in an individual in need thereof comprising co-administering methotrexate and a TNF α antagonist to said individual, in therapeutically effective amounts.
56. (New) The method of Claim 55, wherein said TNF α antagonist and methotrexate are administered simultaneously.
57. (New) The method of Claim 55, wherein said TNF α antagonist and methotrexate are administered sequentially.
58. (New) The method of Claim 55, wherein said TNF α antagonist is administered in multiple doses.
59. (New) The method of Claim 55, wherein said TNF α antagonist prevents or inhibits TNF α synthesis or TNF α release.
60. (New) A method for treating or preventing rheumatoid arthritis in an individual in need thereof comprising co-administering methotrexate and a TNF α antagonist to said

Page 5 cont.

Applicants: Marc Feldmann and Ravinder N. Maini
Serial No.: Not Yet Known
Filed: Herewith
page: 6

individual, in therapeutically effective amounts.

61. (New) The method of Claim 60, wherein said TNF α antagonist and methotrexate are administered simultaneously.
62. (New) The method of Claim 60, wherein said TNF α antagonist and methotrexate are administered sequentially.
63. (New) The method of Claim 60, wherein said TNF α antagonist is administered in multiple doses.
64. (New) The method of Claim 60, wherein said TNF α antagonist prevents or inhibits TNF α synthesis or TNF α release.
65. (New) A method for treating or preventing Crohn's disease in an individual in need thereof comprising co-administering methotrexate and a TNF α antagonist to said individual, in therapeutically effective amounts.
66. (New) The method of Claim 65, wherein said TNF α antagonist and methotrexate are administered simultaneously.
67. (New) The method of Claim 65, wherein said TNF α antagonist and methotrexate are administered sequentially.
68. (New) The method of Claim 65, wherein said TNF α antagonist is administered in multiple doses.
69. (New) The method of Claim 65, wherein said TNF α antagonist prevents or inhibits TNF α synthesis or TNF α release.
-